We are live on ! Find out more
TRCT

Tower Research Capital (TRC) Portfolio holdings

AUM $3.85B
1-Year Est. Return 32.11%
This Fund
S&P 500
This Quarter Est. Return
+5.13%
1 Year Est. Return
+32.11%
3 Year Est. Return
+93.86%
5 Year Est. Return
+112.79%
10 Year Est. Return
+377.38%
AUM
$775M
AUM Growth
-$436M
Cap. Flow
-$471M
Cap. Flow %
-60.72%
Top 10 Hldgs %
18.21%
Holding
4,545
New
711
Increased
1,179
Reduced
1,568
Closed
1,030

Sector Composition

Rank Sector Weight
1 Financials 11.08%
2 Technology 10%
3 Consumer Discretionary 7.02%
4 Healthcare 6.86%
5 Communication Services 6.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PFGC icon
2826
Performance Food Group
PFGC
$17.6B
$6K ﹤0.01%
175
-5,341
-97% -$157K
SUPV
2827
Grupo Supervielle
SUPV
$786M
$6K ﹤0.01%
+198
New +$5.26K
TGT icon
2828
Target
TGT
$67.1B
$6K ﹤0.01%
93
-1,793
-95% -$108K
TRC icon
2829
Tejon Ranch
TRC
$444M
$6K ﹤0.01%
305
-1,101
-78% -$22.7K
TRUP icon
2830
Trupanion
TRUP
$1.06B
$6K ﹤0.01%
188
-1,665
-90% -$49K
VRNT
2831
DELISTED
Verint Systems
VRNT
$6K ﹤0.01%
271
-16,415
-98% -$353K
SUNE
2832
SUNation Energy
SUNE
$10.8M
0
BERY
2833
DELISTED
Berry Global Group, Inc.
BERY
$6K ﹤0.01%
+109
New +$5.93K
NEPT
2834
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$6K ﹤0.01%
1
-2
-67% -$3.63K
PACW
2835
DELISTED
PacWest Bancorp
PACW
$6K ﹤0.01%
127
-1,311
-91% -$62.5K
AMRS
2836
DELISTED
Amyris Inc.
AMRS
$6K ﹤0.01%
+1,555
New +$5.24K
IMBI
2837
DELISTED
iMedia Brands, Inc. Class A Common Stock
IMBI
$6K ﹤0.01%
426
-414
-49% -$5.29K
NYMX
2838
DELISTED
Nymox Pharmaceutical Corp
NYMX
$6K ﹤0.01%
1,851
+141
+8% +$514
CYAD
2839
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
$6K ﹤0.01%
148
+119
+410% +$5.95K
RDS.B
2840
DELISTED
Royal Dutch Shell PLC ADS Class B
RDS.B
$6K ﹤0.01%
86
+7
+9% +$454
SMTX
2841
DELISTED
SMTC Corporation
SMTX
$6K ﹤0.01%
+3,023
New +$4.8K
EQM
2842
DELISTED
EQM Midstream Partners, LP
EQM
$6K ﹤0.01%
88
-64
-42% -$4.57K
MDCO
2843
DELISTED
Medicines Co
MDCO
$6K ﹤0.01%
202
-9,904
-98% -$305K
TIER
2844
DELISTED
TIER REIT, Inc.
TIER
$6K ﹤0.01%
286
-2,339
-89% -$46.1K
GNCA
2845
DELISTED
Genocea Biosciences, Inc.
GNCA
$6K ﹤0.01%
616
-446
-42% -$4.49K
ITG
2846
DELISTED
Investment Technology Group Inc
ITG
$6K ﹤0.01%
300
-4,531
-94% -$91.8K
EQGP
2847
DELISTED
EQGP Holdings, LP
EQGP
$6K ﹤0.01%
240
-3,189
-93% -$86.4K
BYBK
2848
DELISTED
Bay Bancorp, Inc.
BYBK
$6K ﹤0.01%
+500
New +$5.95K
LVNTA
2849
DELISTED
Liberty Interactive Corporation Series A Liberty Ventures
LVNTA
$6K ﹤0.01%
115
+24
+26% +$1.37K
CUDA
2850
DELISTED
Barracuda Networks, Inc.
CUDA
$6K ﹤0.01%
200
-3,557
-95% -$88.3K

Similar funds

Tower Research Capital (TRC)'s Q4 2017 Portfolio in Review

As of Q4 2017, Tower Research Capital (TRC) held 4,545 positions worth $775M, down 36% from $1.21B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Tower Research Capital (TRC) withdrew a net $471M in Q4 2017, closing 1,030 positions and reducing 1,568 holdings. Its most notable exit was iShares MSCI EAFE ETF, an estimated $25.9M position sold in full.

By sector, the portfolio is most concentrated in Financials at 11% of assets, up from 6.3% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Tower Research Capital (TRC) opened a new position in Berkshire Hathaway Class B worth $7.94M.

  • Tower Research Capital (TRC)'s largest Q4 2017 buy was Berkshire Hathaway Class B: 40,072 shares worth $7.94M.
  • Tower Research Capital (TRC) added most to Apple in Q4 2017, an estimated $8.74M increase.
  • Tower Research Capital (TRC)'s biggest Q4 2017 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $223M.
  • Tower Research Capital (TRC) fully exited iShares MSCI EAFE ETF in Q4 2017, selling an estimated $25.9M.
  • Tower Research Capital (TRC)'s ten largest holdings make up 18% of its $775M portfolio in Q4 2017.
  • Tower Research Capital (TRC) opened 711 new positions and closed 1,030 in Q4 2017.
  • Tower Research Capital (TRC)'s portfolio value fell 36% quarter-over-quarter to $775M.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2017, filed 9 Feb 2018.